BF Biosciences First Half Profit Up 77% to Rs347 Million on Volume Surge

BF Biosciences, the biotech and pharmaceutical maker part owned by Ferozsons Laboratories, reported a strong first half. Profit jumped as sales volume climbed sharply and the cost of borrowing eased, a combination that fed straight through to the bottom line.

What the BF Biosciences results showed

BF Biosciences reported profit after tax of Rs347.3 million for the six months ended 31 December 2025, up 77.4 percent from Rs195.8 million in the same period a year earlier. Earnings per share rose to Rs3.93. The driver was the top line. Net revenue came in at about Rs5.1 billion, up roughly 88 percent, which the company put down to a large expansion in sales volume rather than price alone.

The cost side helped too. Gross profit grew about 87 percent to more than Rs2.2 billion, and the gross margin held near 43.4 percent, almost unchanged from a year earlier. That stability matters because it shows the extra sales were not bought by sacrificing margin. Finance costs, the interest the company pays on its borrowing, fell about 41 percent, which lifted profit further. Administrative expenses nearly tripled as the company built out capacity, a sign of investment to support the higher volumes.

Why the result matters for pharma stocks

Pakistan's listed pharmaceutical and biotech companies have had a good run since the deregulation of many drug prices, which let them pass on costs and protect margins. BF Biosciences sits in a specialised corner of that market, with a portfolio built around biotech products through its joint venture roots. When a company can nearly double revenue while keeping its gross margin steady, the read is that demand is real and the product mix is holding up, not that it is discounting to chase sales.

The lower finance cost is its own signal. High interest rates have squeezed many manufacturers, so a 41 percent drop in finance costs points to either less debt or cheaper money, both of which free up cash for the business. The rising administrative spend is the thing to weigh against the result, since it shows the company is spending now to support growth it expects to keep coming.

Which stocks, and why

This is a direct, company specific result for BF Biosciences, and the read is clearly positive. A 77 percent profit rise, near doubled revenue, a steady gross margin and a sharp fall in finance costs make for a high quality half year, in line with the strong stretch across the listed pharma sector. The main standing risks are the durability of drug price deregulation and the cost of imported raw materials, which moves with the rupee.

What to watch

Track whether the volume growth holds into the second half, since this result leaned on volume more than price. Watch the gross margin for any slippage, the trend in finance costs, and how the rising administrative spend feeds into future quarters. The cost of imported inputs and the rupee remain the key external pressures, along with the policy stance on drug pricing.